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Conclusions In RRMS patients, calcium–phosphate metab-
olism is disturbed which increases during disease progression.
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MS  Multiple sclerosis
RRMS  Relapsing–remitting multiple sclerosis
CNS  Central nervous system
IL  Interleukin
UVB  Ultraviolet-B radiation
GCs  Glucocorticoids
EDSS  Expanded Disability Status Scale
SD  Standard deviation
Introduction
Multiple sclerosis (MS) is a chronic inflammatory-demy-
elinating disease of the central nervous system (CNS). The 
aetiology of the disease is not entirely understood. It is 
characterised by multifocal and disseminated in time dam-
age to the CNS with heterogeneous symptomatology and 
the clinical course. Depending on the studied region, the 
prevalence in the general population varies from 5 to 150 
per 100,000 individuals [1].
The first symptoms usually appear between the ages 
of 20 and 40 [2, 3] and the disease is the most frequently 
observed among Caucasians, with a higher prevalence in 
females [4].
Currently, MS is a disease of complex pathogenesis with 
genetic, immunopathological and environmental factors 
Abstract 
Introduction and objectives The purpose of this study 
was to evaluate the concentration of 25-hydroxycholecal-
ciferol and parameters of calcium–phosphate metabolism at 
different periods of relapsing–remitting multiple sclerosis 
(RRMS).
Materials and methods Forty-five patients, residents of 
Poland (49°–50°, N), were enrolled in the study, i.e. 15 
immediately after the diagnosis of RRMS, 15 at the early 
stage and 15 at the advanced stage of RRMS. The results 
were compared to values obtained in 20 age- and sex-
matched controls.
Results Lower serum concentrations of 25-hydroxy-
cholecalciferol and ionised calcium were found in patients 
compared to the control group. In patients with the dis-
ease duration of 5–6 years, concentrations of 25-hydroxy-
cholecalciferol and ionised calcium were lower than in 
patients in the earlier period of RRMS. The inverse and 
clearer direction of changes was found in parathormone 
serum concentration in patients compared to the controls. 
In patients with a longer disease duration, a significantly 
lower 25-hydroxycholecalciferol concentration was found 
in female patients compared to male patients. In patients, 
more frequent 25-hydroxycholecalciferol and unsaturated 
fatty acids’ supplementation was observed compared to the 
controls.
K. Kubicka-Baczyk · B. Labuz-Roszak · K. Pierzchala · 
M. Adamczyk-Sowa · A. Machowska-Majchrzak 
Clinical Department and Chair of Neurology in Zabrze, Medical 
University of Silesia, Katowice, Poland
B. Labuz-Roszak (*) 
Clinical Department and Chair of Neurology in Zabrze, Medical 
University of Silesia, 3-go Maja 13/15, 41-800 Zabrze, Poland
e-mail: beatamaria.pl@hoga.pl
636 J Endocrinol Invest (2015) 38:635–642
1 3
[4, 5]. Epidemiologic studies suggest the prevalence rate 
increase at higher latitudes [6]. The protective effect of 
sunlight seems to be related to the protective action of 
25(OH)D3, which plays an important role in immunologi-
cal processes and in the regulation of calcium–phosphate 
metabolism.
Recent studies have demonstrated that 25(OH)D3 par-
ticipates in cell proliferation and differentiation, and also in 
immunological phenomena [7].
The greatest 25(OH)D3 deficiency was noted in the 
spring and in the winter and also in the elderly. Females 
aged 15–45 years are at a greater risk of 25(OH)D3 defi-
ciency, especially in combination with seasonal variations. 
The peak of incidence is noted between the third and the 
fourth decades of life [8, 9].
To provide complex medical care, it is important to 
determine the indices of calcium–phosphate metabolism in 
patients with MS.
The purpose of the study
The study evaluated the concentration of 25(OH)D3 and the 
indices of calcium–phosphate metabolism depending on 
the sex, number of relapses, degree of motor disability and 
the applied treatment at different stages of relapsing–remit-
ting MS (RRMS).
Materials and methods
Patients with diagnosed RRMS were enrolled in the study, 
according to the McDonald criteria of 2005. The patients 
were selected based on the medical documentation of the 
out-patient neurological clinic and the medical history of 
patients hospitalised between 2009 and 2011 in the Clinic 
of Neurology in Zabrze, Poland.
The enrolment criteria were as follows: diagnosis of 
RRMS according to the McDonald criteria; the current 
degree of disability according to the Expanded Disability 
Status Scale (EDSS) from 0.0 to 3.0 points; inhabitation 
of the Silesian agglomeration (at a latitude of 49°–50°, N); 
performance of the professional work under similar envi-
ronmental conditions; absence of any other chronic dis-
ease except MS, patients’ informed written consent for the 
study. Recruited patients had not followed any diet which 
might have influenced the calcium–phosphate metabolism 
(e.g. diabetic diet, weight-reduction diet, high-protein diet, 
etc.). Patients had not consumed dietary supplements with 
vitamin D before or at the time of the study, and within 
6 months prior to sample collection had not resided in other 
climatic zones.
The exclusion criteria were as follows: CNS demyelinat-
ing syndrome of different aetiology than MS; forms of MS 
other than RRMS; duration of disease longer than 6 years 
and the degree of motor disability >3.0 points according 
to the EDSS; relapse at the time of examination; treatment 
with immunomodulatory agents or glucocorticoids (GCs) 
for the mean duration of 6 or 12 weeks depending on the 
qualification to a study subgroup; diagnosed kidney dis-
ease, gastrointestinal tract and liver diseases, endocrine dis-
orders, menopausal women.
The results were compared to values obtained in 20 age- 
and sex-matched controls who did not differ in terms of 
place of residence or ethnicity.
The study was approved by the Bioethics Committee of 
the Medical University of Silesia in Katowice, Poland.
All enrolled patients were interviewed with particular 
attention paid to the course of RRMS: onset of symptoms, 
year of diagnosis, additional tests, number of relapses 
(exacerbations of the disease manifested with new neuro-
logical symptoms), hospitalisations, previous treatment, 
family and occupational history and comorbidities. Gen-
eral and neurological examination was conducted and the 
degree of motor disability of patients was evaluated using 
the EDSS [10].
In every patient, 5 ml fasting blood sample was obtained 
and daily (24 h) urine sample was collected. Laboratory 
tests evaluated the indices of calcium–phosphate metabo-
lism, the results of which were compared to the applicable 
standards for specific test methods.
Serum concentration of 25(OH)D3 (normal range 11.1–
42.9 ng/ml; 30.4–118.5 nmol/l) and parathormone concen-
tration (normal range 15–65 pg/ml) were assessed using the 
COBAS e 601 analyser (Roche).
Serum phosphorus concentration (normal range 0.81–
1.45 mmol/l), serum calcium concentration (normal 
range 2.1–2.55 mmol/l), alkaline phosphatase concentra-
tion (normal range 30–90 U/l), bone alkaline phosphatase 
concentration (normal range 20–48 U/l), and concentra-
tion of daily urine calcium excretion (normal range 2.5–
6.5 mmol/l/24 h) were assessed using the COBAS c 501 
analyser (Roche).
Ionised calcium concentration (normal range: 1.13–
1.32 mmol/l) was measured directly using ion-selective 
electrodes (RAPID lab 865, Siemens).
Samples for laboratory analyses were collected in April 
and the sun exposure was similar for all the examined 
subjects.
The results were stored in the database prepared specifi-
cally for this purpose in Microsoft EXCEL. STATISTICA 
9.1 was used for the statistical analysis. The result of the 
statistical analysis was considered statistically significant 
if the level of significance was p ≤ 0.05. In data descrip-
tion, the standard statistical parameters were provided, i.e. 
the number N, arithmetic mean X, the SD, median and per-
centages (%). Normal distribution of data was assessed by 
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the Shapiro–Wilk normality test. Statistical significance of 
between-group differences was verified by the Mann–Whit-
ney U test and the Kruskal–Wallis test. The Chi-squared 
test was utilised for comparison of qualified variables.
Results
Forty-five patients with RRMS were divided into three 
groups. The results were compared with the control group 
(Table 1).
In the studied groups, serum ionised calcium concen-
trations differed significantly (p = 0.002). The most sig-
nificant differences regarding the concentrations of ion-
ised calcium were observed between group 1 and group 2 
(p = 0.004), and between group 1 and the individuals in the 
control group who had higher concentrations compared to 
patients in group 1 (p = 0.003) (Tables 2, 3).
An association was found between the mean parathor-
mone concentrations and the disease duration. In group 3, 
the mean serum concentration of parathormone was the 
highest and was above the upper limit of the reference 
range. Newly diagnosed patients had the lowest serum con-
centration of parathormone compared to serum concentra-
tion of parathormone in patients at a more advanced stage 
of the disease as well as in the control group (Table 2).
A decrease in mean concentrations of 25(OH)D3 with 
the disease duration was noted. The mean serum con-
centration of 25(OH)D3 in the studied groups of patients 
was lower compared to the control group (p = 0.007). 
A significant difference in concentrations was demon-
strated between the control group and patients with the 
disease duration of up to 6 months (p = 0.002) or longer 
(p < 0.001) (Tables 2, 3).
Next, the indices of calcium–phosphate metabolism 
were assessed depending on the sex. In group 3 (patients 
with longer disease duration), lower concentrations of 
25(OH)D3 were found in females compared to males. In the 
group of patients with a shorter disease duration (groups 1 
and 2), the mean serum concentration of 25(OH)D3 was 
higher in females compared to males with a similar degree 
of motor disability. The mean serum concentrations of 
parathormone in male patients at the advanced stage of the 
disease (group 3) were higher compared to females. Both 
in females in group 2 and in all patients in group 3, regard-
less of the sex, the mean concentrations of parathormone 
exceeded the upper limit of the reference range (Table 4).
The increase in serum parathormone concentration was 
observed with the increase in relapses (R = 0.51, p < 0.001) 
in the conducted correlation analysis between the number 
of relapses, the degree of disability and the indices of cal-
cium–phosphate metabolism in all patients. No other sig-
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Discussion
The present study showed that in patients with RRMS, serum 
concentrations of 25(OH)D3 and ionised calcium were signifi-
cantly lower compared to healthy individuals and decreased 
with the duration of the disease, with the increase in relapses 
and in females compared to males. However, the concentration 
of parathormone increased significantly as RRMS progressed.
Our results concerning the concentration of 25(OH)D3 
in RRMS patients are compatible with those of some [10, 
Table 2  Laboratory results in the examined groups
X mean, SD standard deviation, Me median, 10 % P, 90 % P percentiles, NS not significant, P level of significance










Serum phosphorus (mmol/l) X 1.07 1.13 1.01 1.06 NS (p = 0.130)
SD 0.23 0.2 0.17 0.16
Me 1.05 1.2 1.03 1.07
10 % P 0.87 0.93 0.88 0.9
90 % P 1.19 1.31 1.18 1.23
Serum calcium (mmol/l) X 2.38 2.37 2.37 2.32 NS (p = 0.160)
SD 0.14 0.2 0.08 0.07
Me 2.40 2.36 2.39 2.31
10 % P 2.20 2.25 2.25 2.25
90 % P 2.56 2.44 2.45 2.42
Serum alkaline phosphatase (U/l) X 57.2 63.9 62 56.7 NS (p = 0.240)
SD 10.7 16.8 18.7 22.1
Me 55 59 56 49
10 % P 45.4 43.4 44.8 38.9
90 % P 72.8 85 88.2 85.4
Serum bone alkaline phosphatase (U/l) X 21.5 22.8 22.1 21.8 NS (p = 0.900)
SD 8.1 7.7 7.2 9.6
Me 22 23 21 20.5
10 % P 12 12.4 15.4 11
90 % P 26.6 32.2 31.2 32.2
Serum ionised calcium (mmol/l) X 1.1 1.14 1.09 1.18 p = 0.002
SD 0.21 0.06 0.05 0.17
Me 1.07 1.14 1.08 1.14
10 % P 0.99 1.07 1.05 1.06
90 % P 1.14 1.2 1.14 1.28
Serum parathormone (pg/ml) X 24.33 61.01 76.7 52.28 p = 0.00001
SD 11.25 34.97 41.97 23.68
Me 22.59 60.1 64.39 48.93
10 % P 7.36 16.06 37.11 27.24
90 % P 36.86 103.22 11582 82.88
Serum 25(OH)D3 (ng/ml) X 20.3 16.91 13.89 26.28 p = 0.007
SD 10.38 8.44 6.48 8.24
Me 17.75 15.59 13.4 28.09
10 % P 9.5 7.41 5.76 16.69
90 % P 31.81 29.29 21.11 38.33
Daily urine calcium excretion (mmol/l/24 h) X 2.36 2.67 3.13 3.79 NS (p = 0.310)
SD 0.98 1.9 2.53 2.68
Me 2.16 1.86 1.67 3.04
10 % P 1.21 1.26 1.29 1.17
90 % P 3.57 5.13 7.47 7.42
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11], but not all [12–15] prior publications (Table 5). Moen 
et al. [12], Kragt et al. [13], Soilu-Hanninen et al. [14], and 
Barnes et al. [15] presented different results obtained in 
Norway, the Netherlands, Finland, Great Britain and North-
ern Ireland. The researchers showed comparable mean 
25(OH)D3 concentrations in patients with MS and healthy 
persons.
In the present study, the relationship between 25(OH)D3 
concentration and the degree of motor disability according to 
the EDSS was also analysed and no correlation was found. 
Contrary results were obtained by Van der Mei et al. [10], Hus-
sein et al. [16] and Smolders et al. [17]. Patients with a higher 
serum concentration of 25(OH)D3 had a better motor ability.
In the present study, an increase was observed in the 
mean concentration of parathormone with disease duration 
and the simultaneous decrease in the mean concentration of 
25(OH)D3.
However, the study results of the Soilu-Hanninen et al. 
were different. They showed lower serum concentrations of 
parathormone and ionised calcium in patients with RRMS 
compared to healthy persons. In the present study, the con-
centrations of mineral metabolism indices (i.e. phosphorus, 
alkaline phosphatase and bone alkaline phosphatase) were 
within the reference range, which is consistent with the 
results obtained in Scandinavia and France [15, 18].
In the present study in patients with RRMS diagnosed 
within 6 months and about 6 years prior to the study, higher 
concentrations of parathormone and ionised calcium were 
found and lower 25(OH)D3 concentrations were observed 
compared to patients with the shortest disease duration. 
This would indicate the influence of disease duration on the 
examined indices. A group of patients with RRMS in whom 
an increased parathormone concentration was observed 
was in remission. This is contrary to the results of Soilu-
Hanninen et al. [7] and Pierrot-Deseilligny et al. [14] who 
examined the mineral metabolism in patients during an MS 
relapse.
Due to the fact that MS occurs more frequently in 
females, in the present study the attention was paid to the 
concentration of the examined indices, depending on the 
sex of patients. According to Kuchuk et al. [19], the larg-
est deficiency of 25(OH)D3 in females appears during the 
greatest fertility between the ages of 15 and 45 years. The 
peak of prevalence for MS occurs at the same time.
Analysing the data from the present study, a significantly 
lower serum concentration of 25(OH)D3 was observed in 
Table 3  The comparisons between pairs of groups for serum ionised 
calcium, parathormone and 25(OH)D3 concentration values (Mann–
Whitney U test)
Significant values (p ≤ 0.05) are in bold
Comparison Ionised calcium Parathormone 25(OH)D3
Group 1–group 2 p = 0.004 p < 0.001 NS (p = 0.300)
Group 1–group 3 NS (p = 0.250) p < 0.001 NS (p = 0.090)
Group 1–control 
group
p = 0.003 p < 0.001 NS (p = 0.060)
Group 2–group 3 p = 0.020 NS (p = 0.590) NS (p = 0.490)
Group 2–control 
group
NS (p = 0.880) NS (p = 0.230) p = 0.002
Group 3–control 
group
p = 0.020 p = 0.050 p < 0.001
Table 4  Parameters of calcium–phosphate metabolism in the examined groups, depending on sex (mean ± SD)
M male, F female
Parameter Sex Group 1 (N = 15) Group 2 (N = 15) Group 3 (N = 15) Control group (N = 20)
Serum phosphorus (mmol/l) M 1.10 ± 0.35 1.07 ± 0.29 1.03 ± 0.17 0.94 ± 0.14
F 1.06 ± 0.12 1.17 ± 0.15 1.00 ± 0.17 1.11 ± 0.14
Serum calcium (mmol/l) M 2.41 ± 0.10 2.35 ± 0.05 2.39 ± 0.04 2.35 ± 0.10
F 2.37 ± 0.16 2.37 ± 0.25 2.37 ± 0.08 2.31 ± 0.06
Serum alkaline phosphatase (U/l) M 63.2 ± 12.7 66.0 ± 21.5 66.0 ± 28.0 76.2 ± 24.3
F 53.2 ± 7.9 62.8 ± 15.2 61.0 ± 17.3 48.4 ± 15.3
Serum bone alkaline phosphatase (U/l) M 20.7 ± 8.0 21.6 ± 6.9 26.3 ± 3.2 28.5 ± 12.1
F 22.1 ± 8.7 23.4 ± 8.4 21.0 ± 7.6 18.9 ± 7.0
Serum ionised calcium (mmol/l) M 1.03 ± 0.04 1.13 ± 0.04 1.06 ± 0.01 1.15 ± 0.12
F 1.14 ± 0.27 1.15 ± 0.08 1.09 ± 0.06 1.19 ± 0.19
Serum parathormone (pg/ml) M 22.72 ± 9.34 47.03 ± 40.56 83.18 ± 48.22 51.55 ± 19.61
F 25.40 ± 12.80 68.00 ± 31.76 75.07 ± 42.48 52.59 ± 25.92
Serum 25(OH)D3 (ng/ml) M 18.22 ± 7.04 14.61 ± 10.35 17.45 ± 6.11 24.48 ± 9.38
F 21.70 ± 12.34 18.05 ± 7.67 13.00 ± 6.50 27.05 ± 7.95
Daily urine calcium excretion (mmol/l/24 h) M 2.24 ± 0.99 4.16 ± 2.63 2.66 ± 1.34 4.76 ± 1.88
F 2.44 ± 1.02 1.92 ± 0.84 3.25 ± 2.78 3.37 ± 2.92
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the course of disease progression. Moreover, in the group 
of patients with a longer disease duration a significantly 
lower 25(OH)D3 concentration in females was detected 
compared to male patients with the similar degree of motor 
disability.
Hussein et al. [13], Kragt et al. [16] and El-Ghoneimy 
et al. [20] evaluated 25(OH)D3 concentration depending 
on the sex of individuals inhabiting regions of different 
sun exposure. Contrary to the results of the present study, 
Hussein et al. [16] and El-Ghoneimy et al. [20] demon-
strated a higher concentration of 25(OH)D3 in healthy 
males compared to females. The authors are of the opin-
ion that the obtained results may be determined by cultural 
and religious factors of the communities inhabiting Arabic 
countries.
Conclusions
In patients with RRMS, serum concentrations of 25(OH)D3 
and ionised calcium were significantly lower compared to 
healthy individuals and decreased with the duration of the 
disease, with the increase in relapses and in females com-
pared to males. However, the concentration of parathor-
mone increased significantly as RRSM progressed.
Due to the geographical location, Poland is one of the 
countries with a high risk of MS incidence. However, stud-
ies on calcium–phosphate metabolism have not been con-
ducted in Poland as yet.
The role of the deficiency of 25(OH)D3 in patients with 
MS immediately after the diagnosis and/or the increasing 
25(OH)D3 deficiency in the course of disease progression 
requires further research as well as the determination of 
indices of mineral metabolism depending on the treatment 
used and in the relapse or remission.
The results of the present study and the available litera-
ture show that it is appropriate to determine the indices of 
calcium–phosphate metabolism, including 25(OH)D3 in 
patients immediately after diagnosing MS and in the course 
of disease progression. Depending on the results, 25(OH)
D3 supplementation should be considered.
Limitation of the study
The limitation of the present study is a small number of 
patients with RRMS and healthy controls. 25(OH)D2 was 
not measured. Further study is planned.
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